Evidence map›Paper›PMID 34583245›Full record

ArticleNeoplasia (New York, N.Y.)2021

RosettaSX: Reliable gene expression signature scoring of cancer models and patients.

Julian Kreis, Boro Nedić, Johanna Mazur, Miriam Urban, Sven-Eric Schelhorn, Thomas Grombacher, Felix Geist, Benedikt Brors, Michael Zühlsdorf, Eike Staub

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Julian KreisDepartment of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany; Faculty of Bioscience, University of Heidelberg, Heidelberg, Germany.
Boro NedićDepartment of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.
Johanna MazurDepartment of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.
Miriam UrbanDepartment of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.
Sven-Eric SchelhornDepartment of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.
Thomas GrombacherDepartment of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.
Felix GeistTherapeutic Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
Benedikt BrorsDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Core Center, Heidelberg, Germany.
Michael ZühlsdorfTherapeutic Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
Eike StaubDepartment of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany. Electronic address: eike.staub@merckgroup.com.
Merck (Germany) · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene expression signatures have proven their potential to characterize important cancer phenomena like oncogenic signaling pathway activities, cellular origins of tumors, or immune cell infiltration into tumor tissues. Large collections of expression signatures provide the basis for their application to data sets, but the applicability of each signature in a new experimental context must be reassessed. We apply a methodology that utilizes the previously developed concept of coherent expression of genes in signatures to identify translatable signatures before scoring their activity in single tumors. We present a web interface (www.rosettasx.com) that applies our methodology to expression data from the Cancer Cell Line Encyclopaedia and The Cancer Genome Atlas. Configurable heat maps visualize per-cancer signature scores for 293 hand-curated literature-derived gene sets representing a wide range of cancer-relevant transcriptional modules and phenomena. The platform allows users to complement heatmaps of signature scores with molecular information on SNVs, CNVs, gene expression, gene dependency, and protein abundance or to analyze own signatures. Clustered heatmaps and further plots to drill-down results support users in studying oncological processes in cancer subtypes, thereby providing a rich resource to explore how mechanisms of cancer interact with each other as demonstrated by exemplary analyses of 2 cancer types.

Indexed as

Gene Expression Regulation, NeoplasticSoftwareTranscriptomeBiomarkers, TumorBreast NeoplasmsComputational BiologyFemaleGene Expression ProfilingHumansLymphoma, Large B-Cell, DiffuseUser-Computer InterfaceWeb BrowserBiomarkers, TumorAnalysesCancer expression profilingCancer subtypesGene expression signatureMultiomics AnalysesWeb service

Identifiers

PMID34583245
PMCPMC8479477
OpenAlexW3203411824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.